Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema

M

Mabwell Bioscience

Status and phase

Completed
Phase 1

Conditions

Diabetic Macular Edema

Treatments

Drug: 9MW0813
Drug: Aflibercept

Study type

Interventional

Funder types

Industry

Identifiers

NCT05324592
9MW0813-2020-CP101

Details and patient eligibility

About

A multicenter, randomized, double-blind, parallel-controlled phase I trial comparing the safety, pharmacokinetics and efficacy of 9MW0813 and aflibercept (EYLEA®) after a single dose in patients with diabetic macular edema (DME).

Full description

This is a multi-center, randomized, double-blind, parallel controlled Phase I clinical trial. The primary objective is to compare the safety of a single intravitreal injection (IVT) of 9MW0813 injection and aflibercept intraocular injection solution (EYLEA®) in DME patients. The secondary objectives are to comparing the pharmacokinetic profile, immunogenicity and efficacy of a single intravitreal injection (IVT) of 9MW0813 injection and aflibercept intraocular injection solution (EYLEA®) in DME patients.

Enrollment

24 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Main inclusion criteria:

  1. Diagnosed with type 1 or type 2 diabetes with HbA1c ≤ 11.0%;
  2. Use ETDRS chart BCVA ≥ 19 letters and ≤ 73 letters (approximately equivalent to Snellen chart equivalent 20/40 to 20/400);
  3. Central retinal thickness (CRT) ≥ 300 μm, (using spectral domain optical coherence tomography);
  4. BCVA ≥ 24 letters in the non-study eye (approximately 20/320 equivalent on the Snellen chart).

Main exclusion criteria:

  1. with proliferative diabetic retinopathy (PDR), excluding inactive, fibrotic PDR;
  2. Vitreous hemorrhage within 30 days before the first administration;
  3. Structural retinal damage involving the fovea (such as retinal pigment epithelium (RPE) atrophy, retinal fibrosis, laser scarring, dense hard exudates), or the investigator believes that the study eye has other factors that may hinder vision after macular edema subsides increased retinal damage;
  4. Existing ophthalmic conditions other than diabetic retinopathy that cause macular edema or vision changes (such as retinal vein occlusion (RVO), choroidal neovascularization, retinal detachment, macular hole, macular retinal traction, epiretinal membrane, etc.) ;
  5. There are iris neovascularization;
  6. Uncontrolled glaucoma (defined as intraocular pressure ≥ 25mmHg after anti-glaucoma drug treatment) or glaucoma-causing cup/optic disc ratio of the study eye >0.8 or previous glaucoma filtering surgery (such as trabeculae); excision, sclerectomy, etc.);
  7. The investigator believes that the cataract may affect the judgment of the examination or test results, or requires surgical treatment during the test;
  8. Aphakia (excluding intraocular lens) or posterior capsule defect (except for YAG laser posterior capsulotomy after intraocular lens implantation within 30 days);
  9. History of vitrectomy.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

24 participants in 2 patient groups

9MW0813
Experimental group
Treatment:
Drug: 9MW0813
aflibercept
Active Comparator group
Treatment:
Drug: Aflibercept

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems